MBOT · Microbot Medical Inc.

Microbot Medical announced its first-ever revenue in Q1 2026 from the limited market release of the LIBERTY Endovascular Robotic System. The company transitioned to full market release early in Q2 2026, and mid-way through Q2, revenue has already exceeded total Q1 revenue. The number of accounts more than doubled since the end of the limited market release, with hospitals in six states adopting the system. Procedures performed include the world's first robotic Prostatic Artery Embolization for BPH and robotic Y-90 radioembolization for liver cancer. Management cited growing commercial momentum, recurring orders, and a strong pipeline. The company expects adoption to accelerate due to updated occupational radiation guidelines from multiple medical societies. This marks a significant milestone for Microbot as it transitions from development to commercial operations.